Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Arvin Eslami, Shaya Alimoghadam, Sahar Khoshravesh, Mahsa Shiriani, Rojina Alimoghadam, Ilad Alavi Darazam
The Human monkeypox virus (mpox) belongs to the Poxviridae family, characterized by double-stranded DNA. A 2022 outbreak, notably prevalent among men who have sex with men, was confirmed by the World Health Organization. To understand shifting prevalence patterns and clinical manifestations, we conducted a systematic review of recent animal and human studies. We comprehensively searched PubMed, Scopus, Web of Science, Cochrane Library, and Clinicaltrials.gov, reviewing 69 relevant articles from 4,342 screened records...
December 9, 2023: Journal of Chemotherapy
#22
JOURNAL ARTICLE
Jonas D Albarnaz, Joanne Kite, Marisa Oliveira, Hanqi Li, Ying Di, Maria H Christensen, Joao A Paulo, Robin Antrobus, Steven P Gygi, Florian I Schmidt, Edward L Huttlin, Geoffrey L Smith, Michael P Weekes
Modified vaccinia Ankara (MVA) virus does not replicate in human cells and is the vaccine deployed to curb the current outbreak of mpox. Here, we conduct a multiplexed proteomic analysis to quantify >9000 cellular and ~80% of viral proteins throughout MVA infection of human fibroblasts and macrophages. >690 human proteins are down-regulated >2-fold by MVA, revealing a substantial remodelling of the host proteome. >25% of these MVA targets are not shared with replication-competent vaccinia. Viral intermediate/late gene expression is necessary for MVA antagonism of innate immunity, and suppression of interferon effectors such as ISG20 potentiates virus gene expression...
December 8, 2023: Nature Communications
#23
JOURNAL ARTICLE
Shengxue Luo, Panli Zhang, Yilin Wang, Yunzhu Huang, Xiaorui Ma, Qitao Deng, Peng Zou, Cong Wang, Ling Zhang, Yiping Li, Yongshui Fu, Tingting Li, Chengyao Li
BACKGROUND: Hepatitis C virus (HCV) vaccines are an urgent need to prevent hepatitis C and its further progression of hepatocellular carcinoma. Since the promising T cell based chimpanzee adenovirus and modified vaccinia virus Ankara vectorial HCV vaccines were failed in clinical phase II trial, the vaccine designs to improve protection efficacy in combination of cellular and humoral immunity have been hypothesized against multi-genotypic HCV. METHODS: Eight HCV vaccine strains were constructed with two novel adenovirus vectors (Sad23L and Ad49L) encoding E1E2 or NS3-5B proteins of HCV genotype (Gt) 1b and 6a isolates, covering 80 % HCV strains prevalent in south China and south-east Asia...
December 5, 2023: Biomedicine & Pharmacotherapy
#24
JOURNAL ARTICLE
Aleix Elizalde-Torrent, Alessandra Borgognone, Maria Casadellà, Luis Romero-Martin, Tuixent Escribà, Mariona Parera, Yaiza Rosales-Salgado, Jorge Díaz-Pedroza, Francesc Català-Moll, Marc Noguera-Julian, Christian Brander, Roger Paredes, Alex Olvera
Despite the important role of gut microbiota in the maturation of the immune system, little is known about its impact on the development of T-cell responses to vaccination. Here, we immunized C57BL/6 mice with a prime-boost regimen using DNA plasmid, the Chimpanzee Adenovirus, and the modified Vaccinia Ankara virus expressing a candidate HIV T-cell immunogen and compared the T-cell responses between individuals with an intact or antibiotic-depleted microbiota. Overall, the depletion of the gut microbiota did not result in significant differences in the magnitude or breadth of the immunogen-specific IFNγ T-cell response after vaccination...
October 30, 2023: Vaccines
#25
JOURNAL ARTICLE
Jonah Kupritz, Savita Pahwa, Suresh Pallikkuth
Mpox is an infectious disease caused by the monkeypox virus (MPXV) belonging to the Orthopoxvirus (OPXV) genus, which includes smallpox and vaccinia virus (VACV). A global mpox outbreak which began in May 2022 has infected more than 88,000 people. VACV-based vaccines provide protection against mpox disease but complicate the use of serological assays for disease surveillance. We tested the reactivity of serum IgG from Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN)-vaccinated ( n = 12) and convalescent mpox-infected ( n = 5) individuals and uninfected, non-vaccinated controls ( n = 32) to MPXV/VACV proteins A27, A29, A30, A35, B16, B21, C19, D6, E8, H3, I1, and L1...
November 15, 2023: Pathogens
#26
JOURNAL ARTICLE
Danielle Nettere, Shakthi Unnithan, Nicole Rodgers, Junsuke Nohara, Paul Cray, Madison Berry, Caroline Jones, Lawrence Armand, Shuk Hang Li, Stella J Berendam, Genevieve G Fouda, Derek W Cain, Taylor N Spence, Joshua A Granek, Clemontina A Davenport, Robert J Edwards, Kevin Wiehe, Koen K A Van Rompay, M Anthony Moody, Sallie R Permar, Justin Pollara
An effective HIV-1 vaccine remains a critical unmet need for ending the AIDS epidemic. Vaccine trials conducted to date have suggested the need to increase the durability and functionality of vaccine-elicited antibodies to improve efficacy. We hypothesized that a conjugate vaccine based on the learned response to immunization with hepatitis B virus could be utilized to expand T cell help and improve antibody production against HIV-1. To test this, we developed an innovative conjugate vaccine regimen that used a modified vaccinia virus Ankara (MVA) co-expressing HIV-1 envelope (Env) and the hepatitis B virus surface antigen (HBsAg) as a prime, followed by two Env-HBsAg conjugate protein boosts...
November 24, 2023: NPJ Vaccines
#27
JOURNAL ARTICLE
Alberto Gómez-Carballa, Guillermo Albericio, Julián Montoto-Louzao, Patricia Pérez, David Astorgano, Irene Rivero-Calle, Federico Martinón-Torres, Mariano Esteban, Antonio Salas, Juan García-Arriaza
Unravelling the molecular mechanism of COVID-19 vaccines through transcriptomic pathways involved in the host response to SARS-CoV-2 infection is key to understand how vaccines work, and for the development of optimized COVID-19 vaccines that can prevent the emergence of SARS-CoV-2 variants of concern (VoCs) and future outbreaks. In this study, we investigated the effects of vaccination with a modified vaccinia virus Ankara (MVA)-based vector expressing the full-length SARS-CoV-2 spike protein (MVA-S) on the lung transcriptome from susceptible K18-hACE2 mice after SARS-CoV-2 infection...
December 2023: Antiviral Research
#28
JOURNAL ARTICLE
Meena S Ramchandani, Anna Berzkalns, Chase A Cannon, Julia C Dombrowski, Elizabeth Brown, Eric J Chow, Elizabeth Barash, Sargis Pogosjans, Daniel Smith, Matthew R Golden
BACKGROUND: Data on modified Vaccinia Ankara (MVA) vaccine effectiveness against mpox in real-world settings are limited. METHODS: We performed a retrospective cohort analysis using Cox proportional hazards regression to estimate the association between vaccination and laboratory-confirmed mpox incidence. Study subjects included all men who have sex with men seen in a sexual health clinic in Seattle, Washington, between 1 January 2020 and 31 December 2022. Subjects' receipt of vaccine and diagnosis with mpox were ascertained from public health vaccine registry and surveillance data...
November 2023: Open Forum Infectious Diseases
#29
JOURNAL ARTICLE
Rana Abdelnabi, Patricia Pérez, David Astorgano, Guillermo Albericio, Winnie Kerstens, Hendrik Jan Thibaut, Lotte Coelmont, Birgit Weynand, Nuria Labiod, Rafael Delgado, Dolores Montenegro, Eugenia Puentes, Esteban Rodríguez, Johan Neyts, Kai Dallmeier, Mariano Esteban, Juan García-Arriaza
The development of novel optimized vaccines against coronavirus disease 2019 (COVID-19) that are capable of controlling the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and the appearance of different variants of concern (VoC) is needed to fully prevent the transmission of the virus. In the present study, we describe the enhanced immunogenicity and efficacy elicited in hamsters by a modified vaccinia virus Ankara (MVA) vector expressing a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein [termed MVA-S(3P)]...
2023: Frontiers in Immunology
#30
JOURNAL ARTICLE
Ángela Bella, Leire Arrizabalaga, Claudia Augusta Di Trani, Jose Gonzalez-Gomariz, Celia Gomar, Joan Salvador Russo-Cabrera, Irene Olivera, Assunta Cirella, Myriam Fernandez-Sendin, Maite Alvarez, Alvaro Teijeira, Cigdem Atay, José Medina-Echeverz, Maria Hinterberger, Hubertus Hochrein, Ignacio Melero, Pedro Berraondo, Fernando Aranda
BACKGROUND: Peritoneal carcinomatosis is an advanced stage of cancer in which the disease has spread to the peritoneal cavity. In order to restore antitumor immunity subverted by tumor cells in this location, we evaluated intraperitoneal administrations of modified vaccinia virus Ankara (MVA) engineered to express single-chain interleukin 12 (scIL-12) to increase antitumor immune responses. METHODS: MVA encoding scIL-12 (MVA.scIL-12) was evaluated against peritoneal carcinomatosis models based on intraperitoneal engraftment of tumor cells...
November 2023: Journal for Immunotherapy of Cancer
#31
REVIEW
Melissa M Christodoulidou, Neil A Mabbott
The Mpox virus (MPXV) is endemic in certain countries in Central and West Africa, where several mammalian species, especially rodents, are natural reservoirs. However, the MPXV can infect nonhuman primates and cause zoonotic infections in humans after close contact with an infected animal. Human-to-human transmission of MPXV can also occur through direct close contact with an infected individual or infected materials. In May 2022 an initial cluster of human Mpox cases was identified in the UK, with the first case confirmed in a patient who had recently travelled to Nigeria...
2023: Immunotherapy advances
#32
JOURNAL ARTICLE
Mario Fontán-Vela, Victoria Hernando, Carmen Olmedo, Ermengol Coma, Montse Martínez, David Moreno-Perez, Nicola Lorusso, María Vázquez Torres, José Francisco Barbas Del Buey, Javier Roig-Sena, Eliseo Pastor, Antònia Galmés Truyols, Francisca Artigues Serra, Rosa María Sancho Martínez, Pello Latasa Zamalloa, Olaia Pérez Martínez, Ana Vázquez Estepa, Amós José García Rojas, Ana Isabel Barreno Estévez, Alonso Sánchez-Migallón Naranjo, Jaime Jesús Pérez Martín, Pilar Peces Jiménez, Raquel Morales Romero, Jesús Castilla, Manuel García Cenoz, Marta Huerta Huerta, An Lieve Dirk Boone, María José Macías Ortiz, Virginia Álvarez Río, María Jesús Rodríguez Recio, María Merino Díaz, Belén Berradre Sáenz, María Teresa Villegas-Moreno, Aurora Limia, Asuncion Diaz, Susana Monge
BACKGROUND: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for individuals at high-risk of mpox, including those receiving pre-exposure prophylaxis for HIV (HIV-PrEP). Our aim was to assess the effectiveness of one dose of MVA-BN vaccine as pre-exposure against mpox virus (MPXV) infection in persons on HIV-PrEP...
October 21, 2023: Clinical Infectious Diseases
#33
JOURNAL ARTICLE
Kim Thi Hoang Do, Stefanie Willenzon, Jasmin Ristenpart, Anika Janssen, Asisa Volz, Gerd Sutter, Reinhold Förster, Berislav Bošnjak
BACKGROUND AND AIMS: Modified Vaccinia virus Ankara (MVA) represents a promising vaccine vector for respiratory administration to induce protective lung immunity including tertiary lymphoid structure, the bronchus-associated lymphoid tissue (BALT). However, MVA expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein (MVA-SARS-2-S) required prime-boost administration to induce high titers of anti-Spike antibodies in serum and bronchoalveolar lavage (BAL)...
2023: Frontiers in Cellular and Infection Microbiology
#34
JOURNAL ARTICLE
Alec W Freyn, Caroline Atyeo, Patricia L Earl, Jeffrey L Americo, Gwo-Yu Chuang, Harini Natarajan, Tiffany R Frey, Jason G Gall, Juan I Moliva, Ruth Hunegnaw, Guha Asthagiri Arunkumar, Clinton O Ogega, Arshan Nasir, Genesis Santos, Rafael H Levin, Anusha Meni, Patricia A Jorquera, Hamilton Bennett, Joshua A Johnson, Michael A Durney, Guillaume Stewart-Jones, Jay W Hooper, Tonya M Colpitts, Galit Alter, Nancy J Sullivan, Andrea Carfi, Bernard Moss
Mpox virus (MPXV) caused a global outbreak in 2022. Although smallpox vaccines were rapidly deployed to curb spread and disease among those at highest risk, breakthrough disease was noted after complete immunization. Given the threat of additional zoonotic events and the virus's evolving ability to drive human-to-human transmission, there is an urgent need for an MPXV-specific vaccine that confers protection against evolving MPXV strains and related orthopoxviruses. Here, we demonstrate that an mRNA-lipid nanoparticle vaccine encoding a set of four highly conserved MPXV surface proteins involved in virus attachment, entry, and transmission can induce MPXV-specific immunity and heterologous protection against a lethal vaccinia virus (VACV) challenge...
October 4, 2023: Science Translational Medicine
#35
JOURNAL ARTICLE
Flavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, Jing Li, Minh Ly, Katelyn Faircloth, Jada Mack-Onyeike, Corinna La Rosa, Sandra Thomas, Qiao Zhou, Jennifer Drake, Cynthia Slape, Paolo Fernando, Wasima Rida, Teodora Kaltcheva, Alba Grifoni, Alessandro Sette, Angela Patterson, Shannon Dempsey, Brian Ball, Haris Ali, Amandeep Salhotra, Anthony Stein, Nitya Nathwani, Michael Rosenzweig, Liana Nikolaenko, Monzr M Al Malki, Jana Dickter, Deepa D Nanayakkara, Alfredo Puing, Stephen J Forman, Randy A Taplitz, John A Zaia, Ryotaro Nakamura, Felix Wussow, Don J Diamond, Sanjeet S Dadwal
Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to vaccination. As part of the safety lead-in portion of a phase 2 clinical trial in patients post HCT/CAR-T for hematological malignancies (HM), we tested the immunogenicity of the synthetic modified vaccinia Ankara-based COVID-19 vaccine COH04S1 co-expressing spike (S) and nucleocapsid (N) antigens...
September 15, 2023: Vaccines
#36
REVIEW
Lior Nave, Ili Margalit, Noam Tau, Ido Cohen, Dana Yelin, Florian Lienert, Dafna Yahav
Prevention of mpox has become an important public health interest. We aimed to evaluate the safety and immunogenicity of the Modified Vaccinia Ankara (MVA) vaccine. We conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs) comparing MVA versus no intervention, placebo, or another vaccine. Outcomes included safety and immunogenicity outcomes. We also performed a systematic review of RCTs evaluating various MVA regimens. Fifteen publications were included in the quantitative meta-analysis...
August 24, 2023: Vaccines
#37
JOURNAL ARTICLE
Sneha Vishwanath, George William Carnell, Matteo Ferrari, Benedikt Asbach, Martina Billmeier, Charlotte George, Maria Suau Sans, Angalee Nadesalingam, Chloe Qingzhou Huang, Minna Paloniemi, Hazel Stewart, Andrew Chan, David Arthur Wells, Patrick Neckermann, David Peterhoff, Sebastian Einhauser, Diego Cantoni, Martin Mayora Neto, Ingo Jordan, Volker Sandig, Paul Tonks, Nigel Temperton, Simon Frost, Katharina Sohr, Maria Teresa Lluesma Ballesteros, Farzad Arbabi, Johannes Geiger, Christian Dohmen, Christian Plank, Rebecca Kinsley, Ralf Wagner, Jonathan Luke Heeney
The threat of spillovers of coronaviruses associated with the severe acute respiratory syndrome (SARS) from animals to humans necessitates vaccines that offer broader protection from sarbecoviruses. By leveraging a viral-genome-informed computational method for selecting immune-optimized and structurally engineered antigens, here we show that a single antigen based on the receptor binding domain of the spike protein of sarbecoviruses elicits broad humoral responses against SARS-CoV-1, SARS-CoV-2, WIV16 and RaTG13 in mice, rabbits and guinea pigs...
September 25, 2023: Nature Biomedical Engineering
#38
JOURNAL ARTICLE
Samuel Schildhauer, Kayla Saadeh, Josh Vance, Joshua Quint, Tarek Salih, Timothy Lo, Awa Keinde, Edwin Chojolan, Esther Gotlieb, Marisa Ramos, Eric Chapman, Philip Peters, Jessica Watson, Kelly A Johnson, Eric C Tang, Kathleen Jacobson, Robert Snyder
The effectiveness of 1 dose of JYNNEOS vaccine (modified vaccinia Ankara vaccine, Bavarian Nordic) against hospitalization for mpox (caused by Monkeypox virus), has been demonstrated; however, the impact of 2 doses on hospitalization risk, especially among persons infected with HIV, who are at higher risk for severe disease, is an important factor in evaluating vaccine effectiveness against mpox disease severity and Monkeypox virus infection. Surveillance data collected by the California Department of Public Health were used to evaluate whether receipt of 2 doses of JYNNEOS vaccine reduced the odds of hospitalization among persons with mpox...
September 8, 2023: MMWR. Morbidity and Mortality Weekly Report
#39
JOURNAL ARTICLE
Junda Zhu, Xintao Gao, Yijing Li, Zihui Zhang, Shijie Xie, Shuning Ren, Yarui Li, Hua Li, Kang Niu, Shufang Fu, Yining Deng, Yinü Li, Bernard Moss, Wenxue Wu, Chen Peng
Zoonotic poxviruses such as mpox virus (MPXV) continue to threaten public health safety since the eradication of smallpox. Vaccinia virus (VACV), the prototypic poxvirus used as the vaccine strain for smallpox eradication, is the best-characterized member of the poxvirus family. VACV encodes a serine protease inhibitor 1 (SPI-1) conserved in all orthopoxviruses, which has been recognized as a host range factor for modified VACV Ankara (MVA), an approved smallpox vaccine and a promising vaccine vector. FAM111A (family with sequence similarity 111 member A), a nuclear protein that regulates host DNA replication, was shown to restrict the replication of a VACV SPI-1 deletion mutant (VACV-ΔSPI-1) in human cells...
August 29, 2023: Proceedings of the National Academy of Sciences of the United States of America
#40
JOURNAL ARTICLE
Sarah E Silk, Wilmina F Kalinga, Ivanny M Mtaka, Nasoro S Lilolime, Maximillian Mpina, Florence Milando, Saumu Ahmed, Ababacar Diouf, Fatuma Mkwepu, Beatus Simon, Thabit Athumani, Mohammed Rashid, Latipha Mohammed, Omary Lweno, Ali M Ali, Gloria Nyaulingo, Bakari Mwalimu, Sarah Mswata, Tunu G Mwamlima, Jordan R Barrett, Lawrence T Wang, Yrene Themistocleous, Lloyd D W King, Susanne H Hodgson, Ruth O Payne, Carolyn M Nielsen, Alison M Lawrie, Fay L Nugent, Jee-Sun Cho, Carole A Long, Kazutoyo Miura, Simon J Draper, Angela M Minassian, Ally I Olotu
BACKGROUND: RH5 is a leading blood-stage candidate antigen for a Plasmodium falciparum vaccine; however, its safety and immunogenicity in malaria-endemic populations are unknown. METHODS: A phase 1b, single-center, dose-escalation, age-de-escalation, double-blind, randomized, controlled trial was conducted in Bagamoyo, Tanzania (NCT03435874). Between 12th April and 25th October 2018, 63 healthy adults (18-35 years), young children (1-6 years), and infants (6-11 months) received a priming dose of viral-vectored ChAd63 RH5 or rabies control vaccine...
August 7, 2023: Med
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
